Myeloid growth factors Journal Article

Authors: Crawford, J.; Armitage, J.; Balducci, L.; Becker, P. S.; Blayney, D. W.; Cataland, S. R.; Heaney, M. L.; Hudock, S.; Kloth, D. D.; Kuter, D. J.; Lyman, G. H.; McMahon, B.; Rugo, H. S.; Saad, A. A.; Schwartzberg, L. S.; Shayani, S.; Steensma, D. P.; Talbott, M.; Vadhan-Raj, S.; Westervelt, P.; Westmoreland, M.; Dwyer, M.; Ho, M.
Article Title: Myeloid growth factors
Abstract: Febrile neutropenia, a common side effect of myelosup-pressive chemotherapy in patients with cancer, can result in prolonged hospitalization and broad-spectrum antibiotic use, often prompting treatment delays or dose reductions of drug regimens. Prophylactic use of myeloid growth factors (mainly the colony-stimulating factors filgrastim and pegfilgrastim) in patients of heightened risk can reduce the severity and duration of febrile neutropenia. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Myeloid Growth Factors provide recommendations on the use of these agents mainly in the oncology setting based on clinical evidence and expert consensus. This version includes revisions surrounding the issue of timing of pegfilgrastim administration. It also includes new sections on tbo-filgrastim, a recently approved agent that is biologically similar to filgrastim, and the role of myeloid growth factors in the hematopoietic cell transplant setting. © JNCCN-Journal of the National Comprehensive Cancer Network.
Journal Title: Journal of the National Comprehensive Cancer Network
Volume: 11
Issue: 10
ISSN: 1540-1405
Publisher: Harborside Press  
Date Published: 2013-10-01
Start Page: 1266
End Page: 1290
Language: English
PROVIDER: scopus
PUBMED: 24142827
Notes: --- - "Export Date: 2 December 2013" - "Source: Scopus"
Citation Impact
MSK Authors
  1. Mark L Heaney
    94 Heaney